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Abstract
Objectives: Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from
glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, incorporating Phases I-III, tested
ceftriaxone in ALS. Stage 1 determined the cerebrospinal fluid pharmacokinetics of ceftriaxone in subjects with ALS. Stage 2
evaluated safety and tolerability for 20-weeks. Analysis of the pharmacokinetics, tolerability, and safety was used to
determine the ceftriaxone dosage for Stage 3 efficacy testing.
Methods: In Stage 1, 66 subjects at ten clinical sites were enrolled and randomized equally into three study groups
receiving intravenous placebo, ceftriaxone 2 grams daily or ceftriaxone 4 grams daily divided BID. Participants provided
serum and cerebrospinal fluid for pharmacokinetic analysis on study day 7. Participants continued their assigned treatment
in Stage 2. The Data and Safety Monitoring Board (DSMB) reviewed the data after the last participants completed 20 weeks
on study drug.
Results: Stage 1 analysis revealed linear pharmacokinetics, and CSF trough levels for both dosage levels exceeding the pre-
specified target trough level of 1 mM (0.55 mg/mL). Tolerability (Stages 1 and 2) results showed that ceftriaxone at dosages
up to 4 grams/day was well tolerated at 20 weeks. Biliary adverse events were more common with ceftriaxone but not dose-
dependent and improved with ursodeoxycholic (ursodiol) therapy.
Conclusions: The goals of Stages 1 and 2 of the ceftriaxone trial were successfully achieved. Based on the pre-specified
decision rules, the DSMB recommended the use of ceftriaxone 4 g/d (divided BID) for Stage 3, which recently closed.
Trial Registration: ClinicalTrials.gov NCT00349622.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a disorder primarily of the
motor neurons, which results in progressive wasting and paralysis
of voluntary muscles [1]. The incidence of ALS is approximately
2/100,000/year [2]. Average age of onset for sporadic ALS is 55–
65 years, though there is a wide variability around this mean, and
mean survival is 3–5 years [3]. Studies demonstrate a modest
survival benefit of riluzole [4,5], but the urgent need for novel
treatments is clear.
ALS pathophysiology is not fully understood, but glutamate
excitotoxicity may be a factor in disease progression. A large body
of research supports the role of excitotoxicity in the pathogenesis
of ALS (reviewed in [6]). Pointedly, transgenic murine ALS
models and human post-mortem tissue have shown decreased
excitatory amino acid transporter 2 (EAAT2; mouse analog
GLT1), which clears synaptic glutamate [7,8,9].
Numerous preclinical studies highlight ceftriaxone as a potential
anti-excitotoxic therapy for patients with ALS. The Neurodegen-
eration Drug Screening Consortium (NDSC) screened 1040
compounds in 29 laboratories using 29 different assays, seven of
which were relevant to putative disease mechanisms in ALS. Beta-
lactam antibiotics were active in the majority of ALS-related
assays, particularly in models related to glutamate excitotoxicity
via EAAT2 and mutant SOD1 (mSOD1) toxicity [10,11].
Ceftriaxone had previously been reported to be neuroprotective
in many in vitro [12] and in vivo models by reducing glutamate
excitoxicity [13,14,15,16,17], though some in vitro models did not
demonstrate neuroprotection [18]. It increases EAAT2 promoter
activation and EAAT2 activity in rodent brains [11], protects
motor neurons in culture from excitotoxicity [10,12], and has
antioxidant activity [19,20]. Finally, ceftriaxone administered to
SOD1
G93A mice at disease onset slowed the disease course,
preserved strength, delayed weight loss, and prolonged survival
[11]. In animal models, ceftriaxone increased GLT1 (mouse
analog of EAAT2) expression. It increased EAAT2 promoter in
human astrocyte cultures at concentrations of 1.0 mM, but not
0.1 mM [11].
In addition to the preclinical data supporting its beneficial
effects in models of ALS, ceftriaxone has been reported as
neuroprotective in vitro [12] and in vivo in other neurologic
diseases, including spinal muscular atrophy [13], Huntington’s
Disease [14] and ischemia [15,16,18], and multiple sclerosis [17].
Ceftriaxone is an FDA-approved beta-lactam antibiotic with
good central nervous system (CNS) penetration. The usual adult
daily dose of intravenous (IV) ceftriaxone is 1–2 grams daily;
maximum dosage is 4 grams daily. The typical duration is less than
four weeks, though it is occasionally used for up to 8 weeks to treat
osteomyelitis or endocarditis. The CSF half-life of ceftriaxone has
been estimated at 16.8 hours in studies of patients with external
ventriculostomies and half-life in blood is 8.5 hours [21,22].
Studies of longer treatment with ceftriaxone are limited
[23,24,25,26,27]. The actual CNS/CSF concentration necessary
to be neuroprotective in human brain or to induce human EAAT2
in vivo are not known.
Given the need for new therapies for the treatment of ALS, and
the large body of research supporting a neuroprotective role for
ceftriaxone, the decision was made to test the safety and efficacy of
ceftriaxone in patients with ALS. A three-stage nonstop drug
development program with intermediate analyses and no pauses
between stages was designed to obtain pharmacokinetic (PK)
(Stage 1) and safety and tolerability (Stage 2) data, and apply this
information to the development of an efficacy study (Stage 3). This
design was chosen as a method to expedite drug development
(Unpublished Data: Presented by Helms, Kesler, Monti, and
Wallace at FDA -ASA BioPharm Section Workshop, 2002). We report
here on results of the first two stages.
Methods
Study Design and Aims
Stage 1 determined the pharmacokinetics (PK) of ceftriaxone in
the plasma and cerebrospinal fluid (CSF) of subjects with ALS.
Stage 2 determined safety and tolerability over 20 weeks. Stage 3
tested the efficacy of ceftriaxone to slow disease progression.
Ethics Statement
The study was conducted under an IND (#68,892), approved
by the Massachusetts General Hospital (MGH) Coordination
Center Institutional Review Board (IRB) and all participating
center IRBs, including Harvard Partners, State University of New
York Upstate Medical University, Washington University in St.
Louis, Wake Forest University, California Pacific Medical Center,
Methodist Neurological Institute, Carolinas Medical Center,
Indiana University, Emory University, and University of Chicago.
The study was listed on clinicaltrials.gov (NCT00349622). The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
An independent Data Safety Monitoring Board (DSMB)
reviewed safety and made recommendations regarding the final
dosage for Stage 3. All coordination center staff, participants,
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"investigators, site coordinators and site evaluators were blinded to
treatment group assignment throughout the study. Screening for
Stages 1 and 2 began in August, 2006 and completed in March
2008.
Stage 1
The aim of Stage 1 was to determine if either dose, or both
doses, of ceftriaxone achieve a CSF trough concentration of
$1 mM in at least 80% of the participants. The PK of ceftriaxone
in plasma and CSF were measured to allow estimation of CSF
levels based on dosing and plasma level. The PK effect of a drug
holiday was also modeled. Participants were randomized equally
into treatment arms receiving placebo twice daily, low dose (2
grams per day in the morning and placebo in the afternoon)
ceftriaxone (LD) or high dose (4 grams per day divided into 2
grams twice daily) ceftriaxone (HD) administered via indwelling
central venous catheter. Placebo was pediatric multivitamin
matching the study drug in appearance, taste, and odor.
Stage 2
The treatment blind was not broken after Stage 1; all subjects
continued treatment in their previously assigned dosage group for
Stage 2 to determine safety and tolerability after 20 weeks,
inclusive of time on study drug in Stage 1. Subjects were regarded
as treatment failures if they permanently discontinued study drug
prior to completing 20 weeks of treatment for any reason. A
dosage was considered tolerable if the proportion of treatment
failures was less than 40% with 80% confidence. Safety was also
assessed, as defined by the occurrence of serious adverse events
(SAEs). Because the study design was non-stop continuous, all
participants remained on study drug at the end of Stage 2.
By design, the DSMB performed an interim analysis and made
a recommendation about dosage for Stage 3. Stage 2 participants
continued to Stage 3 in a blinded fashion. Those on placebo
continued on placebo, those on active treatment had their doses
adjusted to match the selected Stage 3 dosage. New participants in
Stage 3 were randomized to active treatment or placebo in a 2:1
ratio.
Participant Selection Criteria
At screening, eligible participants had a diagnosis of probable
lab-supported, probable, or definite ALS by El Escorial Criteria
[28], a vital capacity (VC) $60% of the predicted normal value for
height, age and gender, symptom duration of less than 3 years, and
were not on riluzole or were on a stable dose for $30 days. Trial
participants were discouraged from starting or stopping riluzole
during the trial but were not prevented from doing so. Exclusion
Figure 1. Enrollment, Randomization, Follow-Up and Analysis.
doi:10.1371/journal.pone.0061177.g001
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to beta-lactam antibiotics, pregnancy, exposure to investigational
agents within 30 days of screening, active gastrointestinal or biliary
disease within 30 days of screening, history of antibiotic-induced
colitis, or clinically significant abnormal safety laboratory values.
Study Procedures
Participants signed an informed consent form prior to screening.
Medical history, physical and neurological examinations, medica-
tion review, VC testing, administration of the revised ALS
functional rating scale (ALSFRS-R), vital signs, electrocardiogram
(ECG), and laboratory tests were performed. Investigators
determined the competence of the participant’s caregiver(s) to
administer the study drug at home. Screening procedures took
place within 28 days of the baseline (randomization) visit.
Following screening and before placement of the catheter,
participants and their caregiver(s) were taught catheter care, signs
of line infection, and aseptic infusion technique. Participants and
caregivers demonstrated their proficiency at these techniques and
passed a catheter-care competency assessment.
Central Venous Catheter Placement
The single-lumen tunneled central venous (CV) catheter was
placed by trained personnel prior to randomization.
Randomization
The randomization scheme developed by the Biostatistics
Center at MGH and assigned each participant to one of the
three treatment arms (placebo, LD or HD ceftriaxone) in equal
proportion. There was an additional randomization to the time of
the lumbar puncture for CSF sampling (2, 4, 6, 8, or 10 hours after
dosing). Subjects were not randomized if they had fever or catheter
complications, or if caregiver was unable to demonstrate catheter
care competency.
Pharmacokinetic Procedures
Seven days after initiating study drug, plasma drug concentra-
tion was measured immediately before and after administration,
and every 2 hours thereafter for 12 hours. Blood samples for pre-
dose plasma trough levels were taken for every participant at weeks
2, 4, 8, and 12. Samples were centrifuged and the plasma
separated and frozen until analysis. Drug concentration in the
CSF was measured immediately preceding administration (hour 0)
and at a single time point following study drug administration (2,
4, 6, 8, or 10 hours post-drug administration). Plasma and CSF
drug concentration analysis was performed by a technician
blinded to dosage level, but not time of collection, using high-
performance liquid chromatography (HPLC) with ultraviolet
detection.
Determination of ceftriaxone in plasma and CSF. For
determination of ceftriaxone in plasma, calibration tubes were
prepared containing varying known concentrations of ceftriaxone
(0, and 5 to 40 ug/mL). Drug-free control human or bovine
plasma (0.1 uL) was added to calibration tubes, and 0.1 uL of
study sample plasma added to other tubes. To each tube was
added 0.1 uL of ammonium acetate buffer (0.1 M, pH 5)
containing cefazolin as internal standard. After addition of
0.5 mL acetonitrile, samples were vortex-mixed and centrifuged.
The supernatant was transferred to a conical tube containing
0.5 mL of chloroform. After vortex mixing and centrifugation, the
upper aqueous layer was transferred to an auto-sampling vial for
HPLC analysis. The HPLC mobile phase was water:methanol:-
triethylamine (750:250:4), at a flow rate of 1.0 mL/min. The
column was Waters micro-Bondapak C18, 3.9 mm 6 30 cm.
Detection was U. V. absorbance at 270 nm. Calibration curves
were linear and passed through the origin. The sensitivity limit was
1.0 ug/mL. Within- and between-day variability did not exceed
15%.
For determination of ceftriaxone in CSF, the method was
modified as follows. To the calibration standards (containing 0,
Table 1. Demographics.
Placebo
(mean/SD)
Ceftriaxone 2 g/day
(mean/SD)
Ceftriaxone 4 g/day
(mean/SD) p-value
Age 51 (11) 49 (10) 54 (13) 0.55
Yrs from Symptom Onset to Diagnosis 0.77 (0.47) 0.99 (0.65) 0.78 (0.43) 0.46
Yrs from Symptom Onset to Screening 1.48 (0.77) 1.60 (0.67) 1.44 (0.60) 0.63
% Male 52% 70% 82% 0.13
% Limb Onset 86% 78% 86% 0.77
% Taking Riluzole 67% 78% 64% 0.56
% Predicted VC 87.4% (15.5%) 94.7% (16.8%) 89.9% (17.1%) 0.24
HHD 21.6 (0.8) 21.3 (0.9) 21.1 (1.1) 0.26
ALSFRS-R 35.2 (5.7) 37.5 (5.7) 36.8 (6.0) 0.47
ALS QOL 429 (70) 457 (65) 405 (64) 0.04
Vd in Liters 2 13.7 13.9 0.88
Vd in Liters/kg 2 0.171 0.171 1.00
T1/2 in Hours 2 9.1 8.0 0.12
Clearance in mL/min 2 17.5 20.5 0.04
Clearance in mL/min/kg 2 0.22 0.25 0.23
VC – Vital Capacity; HHD - Hand-Held Dynamometry; ALSFRS-R – Revised ALS Functional Rating Scale; ALSQOL – ALS Quality of Life Questionnaire; Vd – Volume of
Distribution; T1/2– Half-life; mL – milliliters; min – minutes; kg - kilograms.
doi:10.1371/journal.pone.0061177.t001
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tubes contained 0.2 mL of study CSF.
Safety Procedures
Vital signs, weight, vital capacity and ALSFRS-R were assessed
monthly. Safety blood tests were performed weekly for the first 20
weeks of the study. Ceftriaxone is known to cause biliary sludging,
and site investigators were instructed to treat study participants
with ursodeoxycholic acid (ursodiol) 300 mg twice daily, as
indicated for presence of biliary stones or sludge.
Protocol Deviations
There were 234 protocol exceptions granted: 11 for inclusion/
exclusion criteria (4 placebo, 3 LD, 4 HD), nine for procedures
performed out of order, 23 for a missed procedure, 17 for
methodologic errors regarding sample or study drug processing,
114 for out of window study visits, 11 for patients receiving
prophylactic antibiotic for line placement, 23 for additional labs or
imaging not specified in the protocol, and 26 to correct a blood
draw omitted from the protocol inadvertently. There were 105
protocol violations: three violations for improperly obtained
informed consent, 21 for out of window visits, six for out of
sequence procedures, seven for additional study procedures, 48 for
omitting a test or procedure, six for concomitant use of antibiotics,
eight for methodologic errors regarding outcome measure, sample
or study drug processing, one for a blood draw omitted from the
protocol inadvertently, two for subjects who took an extra dose of
study drug in a day, one for failure to report an SAE
appropriately, one for a patient who initiated co-enzyme Q, and
one for a patient who had a Hickman Catheter placed but was not
entered into the study because the patient did not meet inclusion
criteria.
Statistical Analysis
Distributions of baseline characteristics, demographics and
screening laboratory tests were compared among the three groups
using a Kruskal-Wallis (K-W) test for continuous variables and a
Fisher’s exact test for discrete variables.
Plasma concentrations. Plasma kinetics of ceftriaxone were
consistent with a two-compartment model. Accordingly, plasma
Figure 2. Plasma and CSF Pharmacokinetics. a. Mean and SE plasma ceftriaxone concentrations at corresponding times for both LD and HD
arms. Levels are always higher with HD, relative to LD. b. Pre-dose (trough) plasma levels at Week 1 were highly correlated with the pre-dose levels at
Week 4, indicating that steady-state had been reached by Week 1. Dashed line is the line of identity (y=x). c. Pre-dose CSF and plasma concentrations
were significantly correlated using simple linear regression. The r-square value (0.54) indicates that plasma levels explain about 54% of variability in
CSF levels. The slope of the regression line is about 0.04, indicating that CSF levels are much lower than plasma levels. Assuming that CSF uptake
happens by passive diffusion, the difference is probably explained by plasma protein binding of ceftriaxone. d. Actual CSF concentrations, and the
predicted ‘‘typical’’ concentration curves for the 2 gm/day and 4 gm/day dosage groups. Also shown is the boundary of 1.0 micromolar, equivalent
to 0.55 mg/mL. This is the minimum effective concentration based on in vitro studies and the goal concentration for Stage 1.
doi:10.1371/journal.pone.0061177.g002
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infusion were analyzed by derivative-free weighted nonlinear least-
squares regression analysis (SAS PROC NLIN) to calculate total
volume of distribution using the area method (Vd), apparent half-
life of distribution and elimination, and total clearance [29]. It was
assumed that subjects were at steady-state at the time of the study.
Means were compared using Student’s t-test.
CSF concentrations. CSF ceftriaxone concentrations were
analyzed by nonlinear regression, assuming first-order entry into
and removal from CSF. All data points at each dosage level were
assumed to be independent, and analyzed simultaneously.
Correlation between pre-dose plasma and CSF concentrations
were calculated using simple linear regression.
Safety and Tolerability (Stages 1 and 2). Adverse event
(AE) frequency was categorized using the Common Terminology
Criteria for Adverse Events (CTCAE) Version 4 and analyzed
across treatment groups. Biliary AEs and ursodiol use were
anticipated and specifically analyzed. Changes in laboratory values
relative to baseline were measured weekly for the first 20 weeks of
the study and analyzed by repeated-measures ANOVA.
Log-Rank was used to compare median values for time-to-event
analyses, and Jonckheere-Terpstra (JT) test or Fisher’s Exact test
was used for frequency analyses by treatment group. In
accordance with the intention-to-treat principle, all randomized
participants were included in the primary statistical analyses
according to the treatment group to which they were originally
assigned.
The end of Stage 2 was defined as the time at which the final
participant completed 20 weeks on study drug. For the primary
tolerability analysis only the first 20 weeks of study drug therapy
was analyzed for each participant. For secondary analyses, all
available data for Stages 1 and 2 was analyzed.
The rates of change in VC, ALSFRS-R, and hand-held
dynamometry (HHD) in Stages 1 and 2 of the study remains
blinded through completion of Stage 3. SAS version 9.2 was used
for statistical analyses.
Decision rules for stage 3 dosage level. Dosage level for
Stage 3 was determined based on PK and safety/tolerability. If
both dosage levels were tolerable, achieved $1 mM CSF
concentrations, the higher dose was safe (not significantly more
serious AEs, and no differences between rates of important AEs
(one-sided, p=0.10 level), then the higher dosage would be chosen
for Stage 3. If only the higher dosage level achieved the CSF
concentration target ($1 mM in CSF) and it met tolerability goals,
then it would be chosen for Stage 3. If the higher dosage level were
not tolerable or safe, and the lower dosage level met tolerability
and PK goals, then the lower dosage would be chosen for Stage 3.
If neither dose met PK and/or tolerability goals, then the trial
would end.
Power analysis. With 20 subjects per treatment arm, with
one-sided alpha of 0.10, a conclusion that tolerability was .–40%
could be made with at least 80% confidence if #5 subjects failed to
complete the 20-week study. We had $80% power to observe at
least one occurrence of an AE occurring with a frequency of $8%
in one treatment arm.
Results
Sixty-six subjects were enrolled in Stages 1 and 2 (Figure 1).
Treatment arms were similar on baseline characteristics (Table 1).
The baseline ALS Quality of Life Score was highest in the low-
dose ceftriaxone group and lowest in the high dose ceftriaxone
group (K-W; p=0.044).
Pharmacokinetic Analysis
Ceftriaxone had a mean volume of distribution of 13.8 liters and
a plasma half-life of 8.6 hours. Mean plasma concentration levels
for LD and HD arms are presented in Figure 2a. Trough drug
levels in plasma were highly correlated (r
2=0.86) at 1 and 4 weeks
suggesting steady-state drug levels at day 7 (Figure 2b). Plasma and
Figure 3. Effect of Drug Holiday on CSF Drug Levels. Predictive illustration of the effect of ‘‘drug holidays’’ at steady-state. Drug holiday began
at the arrow (24 hours). Dosing then resumed as usual at 72 hours. Despite the holiday, CSF levels remained above 1 micromolar in the 4 gm/day
group, and fell slightly below 1 micromolar in the 2 gm/day group.
doi:10.1371/journal.pone.0061177.g003
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PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e61177Figure 4. Time to Discontinuation of Study Drug by Treatment Arm (until 20 weeks). Kaplan-Meyer curve showing time to discontinuation
of study drug within the first 20 weeks for patients who discontinued study drug within this time frame. Time to discontinuation of study drug was
not significantly different between treatment arms (p=0.90; Log-Rank). LD – Low Dose Ceftriaxone Arm; HD - High Dose Ceftriaxone Arm.
doi:10.1371/journal.pone.0061177.g004
Table 2. Reasons for Drug Discontinuation in Stages 1 and 2.
Placebo (n=21)
Ceftriaxone 2
g/day (n=23)
Ceftriaxone 4
g/day (n=22)
Pooled Fisher-Exact
p-value
Adverse Event 0 3* 2** 0.17
Catheter-Related Adverse Event 1 0 0 0.32
ALS Progression 1 0 0 0.32
Subject Choice 1 1 1 1.00
Caregiver Choice 1 0 1 0.54
Total 4 4 4 1.00
*Pseudomembranous colitis, Pruritis, Neutropenia.
**Pulmonary edema, Cholelithiasis.
doi:10.1371/journal.pone.0061177.t002
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2=0.54) (Figure 2c). CSF
trough levels for both dosage levels exceeded the prespecified
target trough level of 1 mM (0.55 mg/mL) (Figure 2d). In the HD
arm, modeling predicted that CSF levels would stay above 1 mM
for 72 hours off study drug, enabling drug holidays of up to 72
hours if needed, while in the LD arm, levels dipped below 1 mM
between 48 and 72 hours off drug, necessitating drug holidays be
limited to 48 hours (Figure 3). There was no effect of riluzole on
plasma PK of ceftriaxone.
Tolerability
All dosages met the prespecified criterion for tolerability at 20
weeks (Figure 4). There was no dose-dependent effect on time to
early study medication discontinuation (p=0.90; Figure 4). Four
Figure 5. Cholelithiasis and Biliary Sludging by Treatment Arm. (a) Biliary sludging and cholelithiasis were more common in the low dose
(LD) and high dose (HD) treatment arms than in the placebo treatment arm (p,0.01; Jonckheere-Terpstra). (b) Treatment with ursodiol significantly
shortened event duration when used to treat cholelithiasis and biliary sludging (p,0.001; Log-Rank).
doi:10.1371/journal.pone.0061177.g005
Ceftriaxone for ALS: Design, Safety and PK Results
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e61177participants did not complete the first 20 weeks of treatment in the
placebo group, three in the low-dose ceftriaxone group, and five in
the high-dose ceftriaxone group. Discontinuation was due to AEs
in one subject in the placebo arm, three in the LD arm, and two in
the HD arm. One catheter-related adverse event led to
discontinuation in the placebo arm. ALS progression accounted
for one discontinuation in the placebo arm. Subject choice led to
one discontinuation in each treatment arm. Caregiver choice led
to one discontinuation in the placebo arm and one in the HD arm.
(Table 2; all NS).
Secondary analysis of dosage reduction and temporary drug
suspension was performed using all data collected up to the point
that the final participant had completed 20 weeks on study drug
(completion of Stage 2). The average duration of follow-up for this
analysis was 36 weeks. Drug dosing was temporarily suspended 13
times in 8 patients in the placebo arm, 23 times in 16 patients in
the LD arm, and 16 times in 12 patients in the HD arm
(p=0.046). Dosage was reduced in 1 subject in the placebo arm, 8
in the LD arm, and 8 in the HD arm (p=0.017).
Safety
Based on the pre-specified criteria, ceftriaxone was deemed
acceptably safe at all dosages tested. Occurrence of abdominal
pain and cholelithiasis were more common in ceftriaxone-treated
subjects (p=0.02 and p,0.0001, respectively; Figure 5a). Ursodiol
significantly shortened duration of the event (p,0.001; Figure 5b)
and was used by four subjects in the placebo arm (19%), 13 in the
LD arm (57%), and 13 in the HD arm (59%) (p,0.01). Limb
edema was more common in the placebo arm (p=0.05). No other
AEs differed significantly between arms. Forty-four SAEs were
reported (Table 3). Percutaneous endoscopic gastrostomy (PEG)
tube placement was more common in subjects in the placebo arm
(p,0.02; Fischer’s Exact). No other SAEs were statistically
significantly more common in any of the treatment groups. There
was one death in the HD arm and one in the placebo arm, one of
which occurred after catheter placement but before the subject
received study drug, and was unrelated to the catheter.
Small changes occurred in several of the safety laboratory tests
in Stage 1 (,10%). The only statistically significant changes were
increased bilirubin with treatment at weeks 2 (p,0.01), 12
(p,0.01), and 16 (p,0.05).
Central venous catheter was well tolerated. Six SAEs were
definitely or probably related to the central catheter, including
four line infections, one fever, and one thrombotic event – all
resolved. Probably or definitely related AEs included skin reaction
to tape (2), suture-related problems (2), redness or drainage at the
exit site (5), line displacement/dysfunction (6), pain during
insertion or removal (2), chills/vomiting (2), and non-SAE
infections (2).
Discussion
Stages 1 and 2 of our three-stage continuous study design led to
the efficacy trial without necessitating a pause between study
phases. Stages 1 and 2 provided information about the long-term
use of ceftriaxone, CSF PK in patients without inflamed meninges,
and the dosage required to reach CSF levels of in vitro efficacy
(1 mM) [10,11,12].
Stage 1 met its primary aim, demonstrating that both dosage
levels of ceftriaxone (2 grams and 4 grams daily) achieved CSF
concentrations of $1 mM (0.55 mg/mL). Drug holidays of up to 3
days were possible while maintaining effective CSF drug
concentrations $1 mM in patients receiving high dose (4 gm/d)
ceftriaxone. We confirmed ceftriaxone plasma and CSF kinetics
and determined that approximately 50–55% of the variability of
between-subject CSF concentration of ceftriaxone was attributable
to plasma concentration.
Both dosage levels of ceftriaxone met criteria for tolerability in
Stages 1 and 2. As anticipated, the most common drug related AE
was biliary sludge/cholelithiasis, which were well-managed with
ursodiol and/or temporary drug suspension or reduction, and did
Table 3. Serious Adverse Events.
Adverse Event
All
(% (n/total))
Placebo (% (n/
total)) LD (% (n/total)) HD (% (n/total)) JT p-value
Pooled Rx
Fisher’s p-value
Dyspnea (shortness of breath) 15 (10/66) 19 (4/21) 17 (4/23) 9 (2/22) 0.3665 0.7139
PEG Placement (outpatient) 14 (9/66) 29 (6/21) 9 (2/23) 5 (1/22) 0.0256 0.0242
Cholelithiasis 11 (7/66) 0 (0/21) 13 (3/23) 18 (4/22) 0.0827 0.0874
Line infection 8 (5/66) 10 (2/21) 13 (3/23) 0 (0/22) 0.1942 0.6499
Thrombosis/thrombus/embolism 3 (2/66) 5 (1/21) 0 (0/23) 5 (1/22) 1.0000 0.5385
Pnuemonia 4 (2/66) 0 (0/21) 8 (2/23) 0 (0/22) 0.7846 1.0000
CNS cerebrovascular ischemia 2 (1/66) 0 (0/21) 4 (1/23) 0 (0/22) 1.0000 1.0000
Clostridium difficile colitis 2 (1/66) 0 (0/21) 4 (1/23) 0 (0/22) 1.0000 1.0000
Constipation 2 (1/66) 5 (1/21) 0 (0/23) 0 (0/22) 0.3182 0.3182
Sudden Death 2 (1/66) 0 (0/21) 0 (0/23) 5 (1/22) 0.6515 1.0000
Fever (in the absence of neutropenia) 2 (1/66) 5 (1/21) 0 (0/23) 0 (0/22) 0.3182 0.3182
Subarachnoid hemorrhage 2 (1/66) 0 (0/21) 4 (1/23) 0 (0/22) 1.0000 1.0000
Abdomen Pain NOS 2 (1/66) 5 (1/21) 0 (0/23) 0 (0/22) 0.3182 0.3182
Pancreatitis 2 (1/66) 0 (0/21) 0 (0/23) 5 (1/22) 0.6515 1.0000
Pulmonary edema: 2 (1/66) 0 (0/21) 0 (0/23) 5 (1/22) 0.6515 1.0000
Hysterectomy: 2 (1/66) 5 (1/21) 0 (0/23) 0 (0/22) 0.3182 0.3182
Thrombosis/embolism (vascular access-related) 2 (1/66) 5 (1/21) 0 (0/23) 0 (0/22) 0.3182 0.3182
doi:10.1371/journal.pone.0061177.t003
Ceftriaxone for ALS: Design, Safety and PK Results
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e61177not lead to study drug discontinuation in a dose-dependent
manner. In Stage 3, all participants receiving ceftriaxone also
received ursodiol for the prevention of biliary obstruction.
Other AEs did not occur more commonly with ceftriaxone
treatment relative to placebo. The safety of home administration
of study drug by trained caregivers was excellent and compared
favorably to other studies employing at home catheter access (data
not shown).
Based on the pre-established guidelines, the DSMB reviewed
pharmacokinetic, and safety and tolerability data and recom-
mended continuing to Stage 3 with the high dosage ceftriaxone
(4 g/day divided twice daily). A steering committee subpanel also
reviewed the data and came to the same conclusion. Stage 3 data
collection is now complete and efficacy data is being analyzed and
will be reported in a separate manuscript.
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